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Abstract
The accumulation of advanced glycation endproducts (AGEs) and oxidative stress underlie
the pathogenesis of diabetic complications. In many developing countries, diabetes treat-
ment is unaffordable, and plants such as bitter gourd (or bitter melon;Momordica charantia)
are used as traditional remedies because they exhibit hypoglycaemic properties. This study
compared the antiglycation and antioxidant properties of aqueous extracts ofM. charantia
pulp (MCP), flesh (MCF) and charantin in vitro. Lysozyme was mixed with methylglyoxal
and 0–15 mg/ml ofM. charantia extracts in a pH 7.4 buffer and incubated at 37°C for 3 days.
Crosslinked AGEs were assessed using gel electrophoresis, and the carboxymethyllysine
(CML) content was analyzed by enzyme-linked immunosorbent assays. The antioxidant
activities of the extracts were evaluated using assays to assess DPPH (1,1-diphenyl-2-
picryl-hydrazyl) and hydroxyl radical scavenging activities, metal-chelating activity and
reducing power of the extracts. The phenolic, flavonol and flavonoid content of the extracts
were also determined. All extracts inhibited the formation of crosslinked AGEs and CML in a
dose-dependent manner, with MCF being the most potent. The antioxidant activity of MCF
was higher than that of MCP, but MCP showed the highest metal-chelating activity. MCF
had the highest phenolic and flavonoid contents, whereas MCP had the highest flavonol
content.M. charantia has hypoglycaemic effects, but this study shows thatM. charantia
extracts are also capable of preventing AGE formation in vitro. This activity may be due to
the antioxidant properties, particularly the total phenolic content of the extracts. Thus, the
use ofM. charantia deserves more attention, as it may not only reduce hyperglycaemia but
also protect against the build-up of tissue AGEs and reduce oxidative stress in patients with
diabetes.
Introduction
Diabetes mellitus is characterized by hyperglycaemia, and affected patients are prone to long-
term complications [1, 2]. Hyperglycaemia plays a crucial role in the development of these
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complications via increased protein glycation. Protein glycation occurs via a nucleophilic addi-
tion reaction between a carbonyl group from a reducing sugar and a free protein amino group,
resulting in the formation of freely reversible Schiff bases, which are rapidly rearranged to form
more stable Amadori products. In the presence of transition metals and oxygen, glucose and
Amadori products undergo autoxidation (autoxidative glycation and glycoxidation, respec-
tively) to form free radicals [3, 4]. The free radicals then cause damage to biomolecules in the
body [5].
AGEs may react with cellular receptors for AGEs to produce oxidative stress and proinflam-
matory molecules. AGE accumulation in tissues and oxidative stress underlies the long-term
complications of diabetes mellitus [6]. In developing countries, conventional diabetes treat-
ments are expensive, and traditional plant remedies are often used. The use of several tradi-
tional plant-based preparations, including those fromMomordica charantia (also known as
bitter gourd), as oral hypoglycaemic agents has been the subject of scientific evaluation [7].M.
charantia has been used as a medicinal plant for the management of hypertension and diabetes.
Several studies have reported the antidiabetic and antilipidemic properties ofM. charantia
[8, 9].
The effect ofM. charantia on AGE formation is unknown and deserves attention, as plant-
based preparations could potentially be used as cost effective, non-toxic supplements with anti-
glycation properties to prevent or delay the onset of diabetic complications. In some communi-
ties, the outer green part ofM. charantia (M. charantia flesh, MCF) is normally used for
cooking, whereas in others, the inside of the vegetable (M. charantia pulp, MCP) is used. Char-
antin, a key constituent ofM. charantia, is believed to have potential antidiabetic properties
[10].
In the current study, we evaluated and compared the antioxidant properties of MCP, MCF
and charantin in vitro, as well as their antiglycation properties in terms of inhibiting the forma-
tion of crosslinked AGEs and oxidative AGEs, such as carboxymethyllysine (CML).
Materials and Methods
Materials
All reagents including lysozyme, methylglyoxal, bovine serum albumin (BSA), EDTA,
1,1-diphenyl-2-picryl-hydrazyl (DPPH), Folin-Ciocalteu reagent, ferrous sulfate (FeSO4),
hydrogen peroxide and sodium salicylate were obtained from Sigma-Aldrich (Dorset, UK)
unless mentioned otherwise. Potassium ferricyanide (K3Fe(CN)6) was purchased from Fluka
Chemicals Ltd (Gillingham, UK). The OxiSelect N-(carboxymethyl) lysine (CML) kit was pur-
chased from Cell Biolabs (San Diego, CA, USA). FreshM. charantia was purchased from a
local Asian food store (Manchester, UK). Charantin was obtained from Shaanxi Honghao Bio-
Tech (Shaanxi Province, China).
Preparation of extracts
Aqueous flesh and pulp extracts were prepared according to a method described previously
[11], with some modifications. The flesh and pulp (130 mg of each) ofM. charantia were
extracted using 1.3 ml of methanol. The samples were homogenized in a kitchen blender at the
highest speed setting in 1 minute bursts, for a total burst time of 12 minutes. The homogenized
extract was filtered through cheesecloth. A rotary evaporator was used to evaporate the metha-
nol, and any remaining methanol was evaporated in a 100°C water bath.
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deviation; SDS-PAGE, sodium dodecyl sulfate-
polyacrylamide gel electrophoresis.
Preparation of AGEs
Lysozyme (10 mg/ml) was reacted with 0.1 M methylglyoxal and 0–15 mg/ml MCP, MCF or
charantin in 0.1 M sodium phosphate buffer containing 3 mM sodium azide at pH 7.4, and
then incubated at 37°C for 3 days, after which the samples were removed and stored at −20°C
until analysis [12].
Preparation of CML. CML-modified proteins were prepared using a previously estab-
lished method [13]. BSA (100 mg) was incubated with 3 mg of glyoxylic acid and 10 mg of
NaCNBH3 in 10 ml of 0.2 M sodium phosphate buffer (pH 7.8) at 37°C for 24 hours, after
which the sample was dialyzed against distilled water. Different concentrations (5–15 mg/ml)
of the MCP, MCF and charantin extracts were included in the incubation mixture, depending
on the treatment. After incubation, aliquots were removed and stored at −20°C until further
analysis.
Measurement of crosslinked AGEs by SDS-PAGE
Crosslinked AGEs were assessed using sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE), in which 10 μg of protein was applied to each well, followed by electropho-
resis and Coomassie blue staining of the gels [14]. The gels were photographed using the
GeneSnap program from G Box Chem HR16 Bioimaging system (Syngene, Cambridge, UK).
Bands within the same gel were compared. Integrated density (ID) was measured to analyze
the one-dimensional electrophoretic gels, and the percentage of crosslinked AGEs was calcu-
lated using the following formula:
Formation of crosslinked AGEs ð%Þ ¼ ðID with inhibitorjID without inhibitorÞ  100
Measurement of CML using enzyme-linked immunosorbent assays
(ELISA)
The samples (100 μl) were transferred to 96-well plates and incubated overnight at 4°C; next,
the wells were rinsed twice with 250 μl of phosphate-buffered saline. The plates were blocked
with 200 μl of blocking solution for 2 hours at room temperature with shaking and then
washed three times using 1× washing buffer. Diluted anti-CML primary antibody (100 μl) was
added to the wells, and the plates were then incubated at room temperature for 1 hour with
shaking; all wells were subsequently washed three times using 1× washing buffer. A diluted
HRP-conjugated secondary antibody (100 μl) was added to the wells, and the plates were incu-
bated at room temperature for 1 hour with shaking, and then washed three times using 1×
washing buffer. A warm substrate solution (100 μl) was added to each well, and the plates were
then incubated for 20 minutes at room temperature. The enzyme reaction was stopped by add-
ing 100 μl of stop solution to each well, and the absorbance at 450 nm was determined using a
microplate reader.
Measurement of hydroxyl radical scavenging activity
The hydroxyl radical scavenging activity of MCP, MCF and charantin was measured using a
published method [15], with some modifications. Hydroxyl radical scavenging activity was
assessed by monitoring the hydroxylation of salicylate by the Fe3+–salicylate–hydrogen perox-
ide (H2O2) system. The reaction mixture was composed of 1 ml of FeSO4 (1.5 mM), 0.7 ml of
H2O2 (6 mM), 0.3 ml of sodium salicylate (20 mM) and 1 ml of the extracts (5–15 mg/ml),
which were incubated for 1 hour at 37°C. Absorbance was measured at 562 nm. Mannitol was
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used as a positive control. The hydroxyl radical scavenging activity was calculated as:
Scavenging activity ð%Þ ¼ 1 ðA1  A2Þ
A0
 100
where A0 was the absorbance of the control, A1 was the absorbance in the presence of the
extract and A2 was the absorbance without sodium salicylate.
Measurement of DPPH radical scavenging activity
DPPH radical scavenging activity of extracts was determined using an established procedure
[16]. The extracts (15 mg/ml) of MCP, MCF and charantin were mixed with 0.5 ml of a metha-
nolic solution containing DPPH (0.1 mM) and incubated for 30 min at 37°C in the dark.
Absorbance was measured at 517 nm. Ascorbic acid was used as a positive control. Free radical




A = the absorbance of 0.5 ml of the extracts mixed with 0.5 ml of the DPPH solution.
B = the absorbance of 0.5 ml of the extracts mixed with 0.5 ml of methanol.
Measurement of metal chelating activity
The ability of MCP, MCF and charantin extracts to chelate ferrous ions (Fe2+) was assessed
using a modified version of an established procedure [17]. The reaction mixture was composed
of 0.5 ml of the extract (5–15 mg/ml), 50 μl of FeCl2 (2 mM) and 0.6 ml of deionized water.
The mixture was shaken and incubated at room temperature for 10 minutes. A volume of
100 μl of ferrozine (5 mM) was added, mixed and left for an additional 5 minutes to complex
the residual Fe2+. The absorbance of the Fe2+–ferrozine complex was measured at 562 nm.
EDTA was used as a positive control. The Fe2+-chelating activity of the extract was calculated
using the following formula:
Chelating rate ð%Þ ¼ ½1 absorbance of sample
absorbance of control
 100
Measurement of reducing power
The reducing power of MCP, MCF and charantin was determined using an established proce-
dure [18]. A 2.5 ml volume of the different extracts (15 mg/ml) was mixed with 2.5 ml of 0.2 M
sodium phosphate buffer (pH 6.6) and 2.5 ml of 1% potassium ferricyanide (K3Fe(CN)6). The
mixture was incubated for 30 minutes at 50°C. A 2.5 ml volume of 10% trichloroacetic acid (w/
v) was added to all samples to stop the chemical reactions, which were then centrifuged at
1,000 rpm for 10 minutes. The supernatant (2.5 ml) was removed and added to 2.5 ml of dis-
tilled water and 0.5 ml of 0.1% FeCl3, and the absorbance measured at 700 nm. Distilled water
with no added extracts was used as a blank; ascorbic acid was used as a positive control.
Measurement of total phenolic content
The amounts of the total phenolic compounds in MCP, MCF and charantin were estimated as
described previously [19]. Aliquots of 1 ml of the ethanolic MCP, MCF and charantin extracts
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(10 g/l) were mixed with 5 ml of Folin–Ciocalteu reagent (diluted tenfold) and incubated for 3
minutes at room temperature. A 5 ml volume of a 10% Na2CO3 solution was added, and the
mixture was incubated for 1 hour at room temperature. The method was calibrated using 0.24–
0.30 mg/ml ethanolic gallic acid standards. Absorbance was measured at 760 nm, and the final
results were expressed as mg/g of gallic acid equivalents.
Measurement of total flavonol content
Flavonol content was determined using a colorimetric method [19]. Aliquots of 1 ml of the
ethanolic MCP, MCF and charantin extracts (10 g/l) were mixed with 1 ml of AlCl3 in ethanol
(20 g/l) and 3 ml of sodium acetate in ethanol (20 g/l); the mixture was incubated for 1 hour at
20°C. The standard curve was prepared using 0.0166–0.5 mg/ml rutin ethanolic solutions.
Absorbance was measured at 440 nm and the flavonol content was expressed in milligrams of
rutin per gram of extract.
Measurement of total flavonoid content
Flavonoid content was determined using a previously described colorimetric method [19]. A 1
ml volume of the ethanolic MCP, MCF and charantin extracts (10 g/l) was mixed with equal
volumes of 2% AlCl3 in ethanol (20 g/l). The mixture was shaken and incubated for 40 minutes
at 20°C. Absorbance was measured at 415 nm, and flavonoid content was expressed as milli-
grams of rutin per gram of extract.
Statistical analysis
Statistical analysis was performed using Microsoft Office Excel 2007. The results of each exper-
iment are presentedas mean ± standard deviation (SD). The data were analyzed for significance
using Student’s t-test or analysis of variance (ANOVA). Results with p values 0.05 were
deemed statistically significant.
Results
Effects of MCP, MCF and charantin on AGEs
Methylglyoxal, a highly reactive endogenous metabolite, reacts with lysozyme at a higher rate
than glucose (the major metabolic sugar), resulting in the formation of crosslinked AGEs
within 3 days of incubation (Fig 1, lanes 2). The inclusion of MCP, MCF extracts and charantin
inhibited the formation of methylgloyoxal derived crosslinked AGEs in a dose-dependent man-
ner (Fig 1). Thus, dimerization of lysozyme during the glycation reaction was reduced in a
dose-dependent manner with MCF extracts of 5, 10 and 15 mg/ml, resulting in 40% (p< 0.05),
55% (p< 0.05) and 88% (p< 0.01) inhibition of the formation of crosslinked AGEs, respec-
tively, compared with the control (Fig 1A). The formation of crosslinked AGEs was also signifi-
cantly inhibited when lysozyme was glycated in the presence of the MCP extract, compared
with the control. This inhibition depended on the concentration of MCP used, with the greatest
inhibition (49%, p< 0.001) occurring when a 15 mg/ml MCP extract was used (Fig 1B). Simi-
larly, charantin exhibited the greatest inhibition (55%, p< 0.001) when it was used at a concen-
tration of 15 mg/ml (Fig 1C). Overall, the MCF extract was a more effective inhibitor of AGE
formation than MCP or charantin (Fig 1).
In addition to the evaluation of crosslinked AGE formation, the effect ofM. charantia
extracts on the formation of CML (an oxidative AGE) was also investigated. The positive con-
trol was the amount of CML-modified BSA that was produced by glyoxylic acid. Compared to
the positive control, all the extracts inhibited CML formation, with the strongest inhibition
Momordica charantia and Glycation
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Fig 1. Effects of different concentrations of MCF (A), MCP (B) and charantin (C) on the formation of
crosslinked AGEs. A representative SDS-PAGE gel showing lysozyme (10 mg/ml) incubated alone (lane 1)
or in the presence of 0.1 Mmethylglyoxal (lane 2) in 0.1 M sodium phosphate buffer of pH 7.4 for 3 days at
37°C. The dimer formation resulting from protein crosslinking was determined using different concentrations
of the MCF (A1) and MCP (B1) extracts or charantin (C1): 5 mg/ml (lane 3), 10 mg/ml (lane 4) and 15 mg/ml
(lane 5). Lane 0 contains the marker proteins. The bar charts show the effects of different concentrations of
Momordica charantia and Glycation
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exhibited by the MCF extract (Fig 2). Moreover, the inhibition depended on the concentration
of the extract used. At concentrations of 5 and 15 mg/ml, MCF significantly (p< 0.01) inhib-
ited CML formation by 37% and 61%, respectively. Also at concentrations of 5 and 15 mg/ml,
MCP significantly (p< 0.01) reduced CML formation by 26% and 53%, respectively. Further-
more, charantin at 5 and 15 mg/ml concentrations significantly (p< 0.01) decreased CML for-
mation by 23% and 45%, respectively (Fig 2).
Antioxidant properties of MCP, MCF and charantin
The hydroxyl radical scavenging abilities of the MCP, MCF and charantin extracts were deter-
mined and compared (Fig 3A). The MCP, MCF and charantin extracts increased hydroxyl rad-
ical scavenging activity in a dose-dependent manner (Fig 3A). The MCF extract had a hydroxyl
radical scavenging activity of 70% (p< 0.001) when used at 15 mg/ml whereas that for MCP
extract was 68% (p< 0.001) at the same concentration. Charantin at the same concentration of
15 mg/ml had the lowest hydroxyl radical scavenging activity of 45% (p< 0.001). The hydroxyl
radical scavenging activities of MCP, MCF and charantin were less than that of mannitol, the
latter being used as a positive control with 75% scavenging activity at 15 mg/ml (Fig 3A).
The effects of MCP, MCF and charantin on DPPH radical-scavenging activity are shown in
Fig 3B. The percentage inhibition of free radical activity was used to evaluate the protective
effects of a 15 mg/ml solution of the MCP, MCF and charantin extracts on DPPH radical scav-
enging activity in vitro (Fig 3B). The DPPH radical scavenging activities of MCP, MCF and
charantin extracts were significantly lower than that for the positive control ascorbic acid
MCF (A2), MCP (B2) and charantin (C2) on the formation of crosslinked AGEs relative to the control. The
results are presented as means ± SDs (n = 3). *: p < 0.05, **: p < 0.01, ***: p < 0.001 vs control.
doi:10.1371/journal.pone.0159985.g001
Fig 2. Effects of different concentrations of MCP, MCF and charantin on CML formation. The bar graph
shows the effect of different concentrations (5 and 15 mg/ml) of the MCP, MCF and charantin extracts on
production of CML following glycoxidation of BSA (300 mg) in 0.2 M phosphate buffer, pH 7.8 at 37°C over a
period of 24-hours. The positive control was the amount of CML-modified BSA produced in the absence of
extracts. The results are presented as mean ± SD (n = 3), **: p < 0.01 vs control.
doi:10.1371/journal.pone.0159985.g002
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(p< 0.001; Fig 3B) which showed approximately 85% scavenging of DPPH radicals. The scav-
enging activity of the MCF extract was 55% and higher than that of the MCP (40%) or charan-
tin (45%) extracts (Fig 3B).
MCP, MCF and charantin also increased metal-chelation in a dose-dependent manner (Fig
4). The highest chelating effect was observed at a concentration of 15, then 10 and finally 5 mg/
ml for all three extracts. Of the three, MCP was the most effective with 80% chelation at a con-
centration of 15 mg/ml compared to the 40% for MCF and 30% for charantin at the same con-
centration (Fig 4). EDTA as the positive control had the most potent chelating activity of
approximately 100% at all three concentrations used. Indeed at all concentrations used the che-
lating effects of extracts were significantly lower than that for EDTA (p<0.001). Furthermore,
MCP, MCF and charantin extracts showed significant reducing power, as demonstrated by
their ability to reduce ferric ions to ferrous ions. Indeed, the reducing power of MCP, MCF and
charantin extracts were 83%, 87% and 90% respectively compared to 89% for ascorbic acid the
Fig 3. Radical scavenging activity of different concentrations of MCP, MCF and charantin. (A) The
hydroxyl radical scavenging activity of 5–15 mg/ml extracts of MCP, MCF and charantin was assessed by
monitoring the hydroxylation of salicylate by the Fe3+-salicylate-H2O2 system over a period of 30 minutes at
37°C. Mannitol was used as a positive control. (B) The DPPH radical scavenging activity of 15 mg/ml extracts
of MCP, MCF and charantin at 37°C over a period of 30 minutes was also assessed. Ascorbic acid was used
as a positive control. All results are presented as mean ± SD (n = 3). ***: p <0.001 vs control.
doi:10.1371/journal.pone.0159985.g003
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PLOS ONE | DOI:10.1371/journal.pone.0159985 August 11, 2016 8 / 14
positive control (Fig 5). There was no statistical difference between the reducing power of the
three extracts and the ascorbic acid. Thus at the concentrations used, all three extracts had
effective reducing power similar to ascorbic acid.
The phenolic content of the extracts differed significantly (Fig 6A). The MCF extract had a
significantly higher (p< 0.05) phenolic content (175.33 ± 2.30 mg/g of gallic acid equivalents)
than that of the MCP extract (134.66 ± 1.15 mg/g) and the charentin extract (81 ± 1.51 mg/g;
Fig 6A). However, in contrast the highest flavonol content was observed in the MCP extract,
Fig 4. Metal chelating activity of different concentrations of MCP, MCF and charantin.Chelating effects
of 5–15 mg/ml of MCP, MCF and charantin extracts were determined over a period of 10 minutes at room
temperature using the ferrozine method. EDTA was used as a positive control. The results are presented as
mean ± SD (n = 3). ***: p <0.001 vs control.
doi:10.1371/journal.pone.0159985.g004
Fig 5. The reducing power of 15 mg/ml extracts of MCP, MCF and charantin.Reducing power of MCP,
MCF and charantin (15 mg/ml) extracts were determined over a period of 30 minutes at 50°C using the
potassium ferricyanide method. Ascorbic acid was used as a positive control. The results are presented as
mean ± SD (n = 3). There was no significant difference between the extracts and ascorbic acid.
doi:10.1371/journal.pone.0159985.g005
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Fig 6. Total phenolic, flavonol and flavonoid contents of 10 mg/ml solutions of MCP, MCF and
charantin. (A) phenolic content was determined using the Folin-Ciocalteau method calibrated using gallic
acid standards with the results expressed as mg/g of gallic acid equivalents, (B) flavonol content was
determined using the AlCl3 method where the method was calibrated using rutin and results expressed as mg
of rutin per g of extract and (C) flavonoid contents of the ethanolic MCP, MCF and charantin extracts
determined by a colorimetric method calibrated using rutin and the results expressed as mg of rutin per g of
extract. The results are presented as mean ± SD (n = 3). *: p < 0.05, **: p < 0.01.
doi:10.1371/journal.pone.0159985.g006
Momordica charantia and Glycation
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with a value of 47.86 ± 0.91 mg/g of rutin equivalent, whereas the values for the MCF extract
and charantin were 41.11 ± 1.38 mg/g and 30.33 ± 1.90 mg/g, respectively (Fig 6B). The flavo-
noid contents ranged from as high as 134.67 ± 1.89 mg/g of rutin equivalent in the MCF extract
to as low as 64.55 ± 2.03 mg/g in the MCP extract (Fig 6C). Indeed, the total flavonoid content
of the MCF extract was significantly higher (p< 0.05) than that of the MCP and charantin
extracts (Fig 6C).
Discussion
Protein glycation results in the accumulation of AGEs, which cause protein modifications that
result in structural and functional impairments and the formation of intra- and inter-protein
crosslinking [20]. The accumulation of crosslinked AGEs in tissues is believed to be one factor
responsible for the long-term complications of diabetes and aging [3]. Studies have shown that
a range of medicinal plants can reduce AGE formation in vitro, which suggests that such plants
could potentially provide protection against the development of such complications [20, 21].
One of the best studied medicinal plants with antidiabetic effects isM. charantia [10], a plant
with known hypoglycaemic properties in both animals [22] and humans.
In the present study, the antiglycation and antioxidant properties of MCP, MCF and char-
antin extracts fromM. charantia were studied in vitro. The experiments involved in vitro pro-
tein glycation by incubation with methylglyoxal at physiological pH, although a non-
physiological concentration of methylglyoxal was used to accelerate AGE formation over a
shorter time period. Lysozyme was used because it is a good model protein for the measure-
ment of crosslinked AGEs, as oligomerization occurs readily and is easily measurable by
SDS-PAGE. The glycation of lysozyme in vitro has been examined in several previous studies
[23]. In this study, MCP and MCF extracts and charantin showed potent dose-dependent
inhibitory effects on methylglyoxal-induced AGE formation in vitro. The ability of certain
plant extracts to inhibit the formation of AGEs is thought to be related to their antioxidant
properties, and particularly their ability to scavenge radicals formed during the glycation reac-
tion [24, 25].
We showed thatM. charantia extracts have antioxidant effects (in that they inhibited free
radical activity), and that they also possessed antiglycation potential. Indeed, this protection
against glycation-induced crosslinking may be related to the ability of the extracts to chelate
transition metals, which was shown in the current study and could potentially prevent autoxi-
dative glycation and glycoxidation reactions. In a previous study,M. charantia extracts were
shown to chelate Cu2+ ions and protect against low-density lipoprotein oxidation [26].
MCF had a more potent inhibitory effect on the formation of AGEs compared with MCP
and charantin, which might be attributed to its higher phenolic and flavonoid content. Several
studies have demonstrated thatM. charantia contains numerous amino acids that might
reduce AGE formation by blocking the carbonyl groups on glycated proteins [27]. CML is
among the most abundant AGE produced in vivo from glycation and oxidation reactions [28].
Elevated CML levels have been identified in diabetic animal and human tissues [29, 30]. The
current study confirms that all threeM. charantia extracts can inhibit CML formation in vitro,
with MCF having the most potent effect. Several studies have shown thatM. charantia signifi-
cantly lowers blood glucose concentrations in diabetic patients [31] and in diabetic rats [10].
These study findings indicate thatM. charantia extracts might reduce AGE formation by low-
ering glucose levels.
Low-molecular-weight antioxidant compounds, such as polyphenols, flavonoids and flavo-
nols, have been identified inM. charantia [25, 32]. The results of the present study show that
MCF extract, which contains a significantly higher phenolic content than MCP or charantin,
Momordica charantia and Glycation
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shows the greatest antioxidant activity. Polyphenolic compounds might be responsible for the
free radical scavenging activities associated withM. charantia extracts. A report has suggested
a relationship between the free radical scavenging activity of polyphenolic substances and their
chemical structures [33]. Other amine-group-containing molecules may be present in the
extract that are capable of reacting with methylglyoxal, thus protecting the amino groups in
proteins from being glycated. Indeed, other antioxidant molecules may be present in the extract
that can protect against autoxidative glycation, thus reducing the formation of AGEs. Addi-
tionally, the possibility of synergistic effects between different extract constituents cannot be
ignored and are often viewed as an advantage of using extracts.
This study investigated the theory that phenolic compounds in certain plant extracts effec-
tively inhibit the formation of AGEs. Thus, phenolic substances can play an important role in
antiglycation and antioxidant activities. All extracts in the current study inhibited the forma-
tion of AGEs, with MCF being the most potent. In addition, all extracts had antioxidant prop-
erties and reduced oxidative stress. The metal chelating activity of these extracts probably has a
major role in their ability to inhibit AGE formation [34].
A pilot study has been conducted involving a double-blinded, placebo controlled trial in
which type 2 diabetic patients were given either 6g/day ofM.charantia pulp or placebo for
16-weeks [35]. After this period, there was a significant reduction of both glycated haemoglo-
bin (HbA1c) and serum fluorescent AGEs [35]. However, it is known thatM.charantia has
hypoglycaemic properties thus the reduction in serum AGEs might be due to better glycaemic
control rather than a direct effect of the extract on AGE formation. Furthermore, this study did
not measure markers of oxidative stress. Our studies albeit in vitro demonstrates thatM.char-
antia extracts have a direct protective effect against AGE formation and oxidative stress. While
this manuscript was being prepared, another study also demonstrated the antiglycation proper-
ties ofM. charantia extracts, thus confirming our studies [36]. Although some evidence exists
that the consumption ofM. charantia can reduce hyperglycaemia, it is not clear whether there
is a direct effect on reduction of AGEs in vivo. However,M.charantia deserves more attention
as a low-cost food for diabetes management with the possibility of protection against diabetes-
induced complications.
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